

# Masamitsu Yanada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7948469/publications.pdf>

Version: 2024-02-01

147  
papers

3,488  
citations

186265

28  
h-index

161849

54  
g-index

148  
all docs

148  
docs citations

148  
times ranked

3399  
citing authors

#	ARTICLE	IF	CITATIONS
1	High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed <i>BCR-ABL</i> <sup>+</sup> Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 460-466.	1.6	430
2	Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. <i>Leukemia</i> , 2005, 19, 1345-1349.	7.2	267
3	Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. <i>Blood</i> , 2004, 104, 3507-3512.	1.4	173
4	Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission. <i>Cancer</i> , 2005, 103, 1652-1658.	4.1	169
5	Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia. <i>Cancer</i> , 2006, 106, 2657-2663.	4.1	153
6	Syndecan-4 Deficiency Leads to High Mortality of Lipopolysaccharide-injected Mice. <i>Journal of Biological Chemistry</i> , 2001, 276, 47483-47488.	3.4	125
7	Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. <i>European Journal of Haematology</i> , 2007, 78, 213-219.	2.2	112
8	Prospective monitoring of <i>BCR-ABL1</i> transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. <i>British Journal of Haematology</i> , 2008, 143, 503-510.	2.5	84
9	Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. <i>Blood</i> , 2013, 121, 3095-3102.	1.4	70
10	Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. <i>Bone Marrow Transplantation</i> , 2009, 44, 43-49.	2.4	64
11	Acute myeloid leukemia in older adults. <i>International Journal of Hematology</i> , 2012, 96, 186-193.	1.6	64
12	Clinical Significance of FLT3 in Leukemia. <i>International Journal of Hematology</i> , 2005, 82, 85-92.	1.6	61
13	Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. <i>Blood</i> , 2002, 99, 2455-2458.	1.4	59
14	Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. <i>Haematologica</i> , 2008, 93, 287-290.	3.5	59
15	Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. <i>Bone Marrow Transplantation</i> , 2004, 34, 331-337.	2.4	56
16	Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3729-3735.	1.6	53
17	Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 601-609.	1.3	51
18	Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 801-807.	2.4	50

#	ARTICLE	IF	CITATIONS
19	Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2005, 36, 867-872.	2.4	44
20	Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1263-1265.	3.5	40
21	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. <i>Bone Marrow Transplantation</i> , 2019, 54, 1789-1798.	2.4	39
22	Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice. <i>Leukemia and Lymphoma</i> , 2006, 47, 1747-1753.	1.3	38
23	Micafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients with Febrile Neutropenia. <i>Internal Medicine</i> , 2006, 45, 259-264.	0.7	38
24	D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. <i>Annals of Hematology</i> , 2017, 96, 1641-1652.	1.8	37
25	Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. <i>European Journal of Haematology</i> , 2005, 74, 418-423.	2.2	35
26	The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. <i>Hematological Oncology</i> , 2017, 35, 87-93.	1.7	32
27	Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation. <i>European Journal of Haematology</i> , 2006, 77, 282-287.	2.2	31
28	Potential cure of acute myeloid leukemia. <i>Cancer</i> , 2007, 110, 2756-2760.	4.1	30
29	Allogeneic myeloablative transplantation for patients aged 50 years and over. <i>Bone Marrow Transplantation</i> , 2004, 34, 29-35.	2.4	29
30	Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. <i>Haematologica</i> , 2012, 97, 915-918.	3.5	29
31	Multiplex Real-time RT-PCR for Prospective Evaluation of WT1 and Fusion Gene Transcripts in Newly Diagnosed De Novo Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1803-1808.	1.3	27
32	Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. <i>Leukemia</i> , 2019, 33, 358-370.	7.2	27
33	Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. <i>Bone Marrow Transplantation</i> , 2021, 56, 1126-1133.	2.4	27
34	Relapse and death during first remission in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 633-634.	3.5	26
35	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. <i>Annals of Hematology</i> , 2020, 99, 1351-1360.	1.8	26
36	Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1505-1509.	0.8	25

#	ARTICLE	IF	CITATIONS
37	Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2009, 89, 3-13.	1.6	25
38	Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. <i>Haematologica</i> , 2013, 98, 1525-1531.	3.5	25
39	Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1447-1454.	2.0	23
40	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 334.e1-334.e11.	1.2	23
41	Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. <i>International Journal of Hematology</i> , 2008, 87, 210-216.	1.6	22
42	TP53 mutations in older adults with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2016, 103, 429-435.	1.6	22
43	Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide. <i>Leukemia and Lymphoma</i> , 2017, 58, 1061-1067.	1.3	22
44	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. <i>International Journal of Hematology</i> , 2015, 101, 243-254.	1.6	21
45	Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1125-1132.	2.0	21
46	Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2015, 106, 1576-1581.	3.9	20
47	Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1123-1125.	1.3	20
48	Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. <i>International Journal of Hematology</i> , 2011, 93, 624-632.	1.6	19
49	Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. <i>Bone Marrow Transplantation</i> , 2019, 54, 578-586.	2.4	17
50	Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan. <i>International Journal of Hematology</i> , 2020, 111, 93-102.	1.6	17
51	Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2105-2114.	2.0	17
52	The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1257-1265.	2.4	16
53	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1132-1138.	7.2	16
54	Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	16

#	ARTICLE	IF	CITATIONS
55	Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: A low initial white blood cell count, as well as a high count predict decreased survival rates. <i>Leukemia Research</i> , 2007, 31, 907-914.	0.8	15
56	Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. <i>Annals of Hematology</i> , 2020, 99, 2787-2800.	1.8	15
57	<i>&lt;i&gt;&lt;scp&gt;ETV6&amp;#x2193;PAXN&lt;/scp&gt;&lt;/i&gt;</i> fusion transcript generated by t(11;12)(q12.1;p13) in a patient with relapsing acute myeloid leukemia with <i>&lt;i&gt;&lt;scp&gt;NUP98&amp;#x2193;HOXA9&lt;/scp&gt;&lt;/i&gt;</i> . <i>Genes Chromosomes and Cancer</i> , 2016, 55, 242-250.	2.8	14
58	Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. <i>European Journal of Haematology</i> , 2016, 97, 278-287.	2.2	14
59	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. <i>Clinical Cancer Research</i> , 2021, 27, 4825-4835.	7.0	14
60	Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 463-471.	2.0	13
61	Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 387-394.	2.4	13
62	Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 390-395.	2.4	12
63	A varicella outbreak in B-cell lymphoma patients receiving rituximab-containing chemotherapy. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 774-777.	1.7	12
64	Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. <i>Bone Marrow Transplantation</i> , 2015, 50, 40-44.	2.4	12
65	Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 307-315.	2.0	12
66	Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan. <i>International Journal of Hematology</i> , 2008, 88, 154-158.	1.6	11
67	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study. <i>Bone Marrow Transplantation</i> , 2017, 52, 818-824.	2.4	11
68	Decision Analysis of Allogeneic Hematopoietic Stem Cell Transplantation Versus Chemotherapy in Cytogenetically Standard-Risk Acute Myeloid Leukemia in First Complete Remission: The Impact of FLT3-ITD Profile. <i>Blood</i> , 2014, 124, 1221-1221.	1.4	11
69	The demarcation between younger and older acute myeloid leukemia patients: A pooled analysis of 3 prospective studies. <i>Cancer</i> , 2013, 119, 3326-3333.	4.1	10
70	Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 289-297.	1.8	10
71	Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1543-1551.	2.0	10
72	FLT3-targeted treatment for acute myeloid leukemia. <i>International Journal of Hematology</i> , 2022, 116, 351-363.	1.6	10

#	ARTICLE	IF	CITATIONS
73	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1398-1404.	2.0	9
74	Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission. <i>Bone Marrow Transplantation</i> , 2019, 54, 2004-2012.	2.4	9
75	Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 2779-2787.	2.4	9
76	Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy. <i>International Journal of Hematology</i> , 2012, 96, 516-520.	1.6	8
77	Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia. <i>Annals of Hematology</i> , 2019, 98, 2179-2186.	1.8	8
78	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	2.4	8
79	Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4694.	4.1	8
80	Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. <i>Leukemia Research</i> , 2016, 51, 11-18.	0.8	7
81	Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. <i>Bone Marrow Transplantation</i> , 2020, 55, 2008-2016.	2.4	7
82	Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. <i>Bone Marrow Transplantation</i> , 2021, 56, 2302-2304.	2.4	7
83	&lt;b&gt;&lt;i&gt;NUP214-RAC1&lt;/i&gt;&lt;/b&gt; and &lt;b&gt;&lt;i&gt;RAC1-COL12A1&lt;/i&gt;&lt;/b&gt; Fusion in Complex Variant Translocations Involving Chromosomes 6, 7 and 9 in an Acute Myeloid Leukemia Case with &lt;b&gt;&lt;i&gt;DEK-NUP214&lt;/i&gt;&lt;/b&gt;. <i>Cytogenetic and Genome Research</i> , 2015, 146, 279-284.	1.1	6
84	Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1&acaron;RUNX1T1 leukemia with t(8;12;21). <i>International Journal of Hematology</i> , 2018, 108, 208-212.	1.6	6
85	Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning. <i>Leukemia and Lymphoma</i> , 2019, 60, 1493-1502.	1.3	6
86	The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse. <i>International Journal of Hematology</i> , 2020, 112, 200-209.	1.6	6
87	Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. <i>Annals of Hematology</i> , 2021, 100, 1849-1861.	1.8	6
88	Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 314.e1-314.e10.	1.2	6
89	Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Annals of Hematology</i> , 2022, 101, 643-653.	1.8	6
90	Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. <i>International Journal of Oncology</i> , 2007, 31, 313-22.	3.3	6



#	ARTICLE	IF	CITATIONS
91	High incidence of secondary failure of platelet recovery after autologous and syngeneic peripheral blood stem cell transplantation in acute promyelocytic leukemia. <i>Bone Marrow Transplantation</i> , 2007, 40, 773-778.	2.4	5
92	Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2007, 138, 555-557.	2.5	5
93	Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study. <i>International Journal of Hematology</i> , 2013, 98, 231-236.	1.6	5
94	Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies. <i>International Journal of Infectious Diseases</i> , 2013, 17, e385-e390.	3.3	5
95	Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease. <i>Bone Marrow Transplantation</i> , 2020, 55, 249-252.	2.4	5
96	Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature. <i>Cancers</i> , 2020, 12, 1444.	3.7	5
97	Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 78-82.	2.4	5
98	Combination of Intensive Chemotherapy and Imatinib (IDEAMOP Regimen) for the Treatment of Newly Diagnosed BCR-ABL Positive Acute Lymphoblastic Leukemia; Excellent Efficacy without Increasing Toxicity.. <i>Blood</i> , 2004, 104, 2736-2736.	1.4	5
99	Randomized controlled trials of treatments for hematologic malignancies. <i>Cancer</i> , 2007, 110, 334-339.	4.1	4
100	Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: a single-center experience. <i>Hematology</i> , 2013, 18, 74-80.	1.5	4
101	The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy. <i>International Journal of Hematology</i> , 2015, 102, 35-40.	1.6	4
102	Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4457-4457.	1.4	4
103	A Comparison of the Outcomes of Autologous and Unrelated-Donor Transplantation in Adult Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S30-S31.	2.0	3
104	Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28181.	1.5	3
105	Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia. <i>Internal Medicine</i> , 2020, 59, 2419-2421.	0.7	3
106	The Prognostic Impact of KIT D816 Mutations in Core Binding Factor Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2785-2785.	1.4	3
107	Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. <i>Cytotherapy</i> , 2022, 24, 1013-1025.	0.7	3
108	Cloning and Characterization of the Murine Antithrombin Gene. <i>Thrombosis Research</i> , 2000, 100, 179-183.	1.7	2

#	ARTICLE	IF	CITATIONS
109	Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (<scp>JSHCT</scp>). <i>British Journal of Haematology</i> , 2018, 182, 245-250.	2.5	2
110	Rare case of Richter syndrome with testicular involvement successfully obtained good prognosis with rapid operation and immunochemotherapy. <i>IJU Case Reports</i> , 2019, 2, 232-235.	0.3	2
111	Prognostic Impact of the Fractionation of Total Body Irradiation for Patients with Acute Myeloid Leukemia Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 185.e1-185.e6.	1.2	2
112	Personalized prediction of overall survival in patients with AML in non-€complete remission undergoing allo-€HCT. <i>Cancer Medicine</i> , 2021, 10, 4250-4268.	2.8	2
113	Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. <i>Blood Cancer Journal</i> , 2021, 11, 159.	6.2	2
114	Final Results From SENSOR: Switch to Nilotinib After Molecular Suboptimal Response (SoR) to Frontline Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2014, 124, 1815-1815.	1.4	2
115	Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML. <i>Blood</i> , 2020, 136, 2-3.	1.4	2
116	Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch. <i>Bone Marrow Transplantation</i> , 2022, 57, 1171-1179.	2.4	2
117	Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. <i>International Journal of Oncology</i> , 2007, , .	3.3	1
118	Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT. <i>Annals of Hematology</i> , 2020, 99, 2927-2937.	1.8	1
119	Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1720-1722.	2.4	1
120	Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1005.e1-1005.e8.	1.2	1
121	Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.. <i>Blood</i> , 2005, 106, 1134-1134.	1.4	1
122	Impact of Antithrombin Deficiency on Efficacies of DU-176b, a Novel Orally Active Direct Factor Xa Inhibitor, and Antithrombin Dependent Anticoagulants, Fondaparinux and Heparin.. <i>Blood</i> , 2005, 106, 1874-1874.	1.4	1
123	Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation during First Complete Remission Following Imatinib-Combined Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 462-462.	1.4	1
124	Effect of allogeneic stem cell transplantation in patients with minimally differentiated acute myeloid leukemia. <i>Journal of Hematopoietic Cell Transplantation</i> , 2019, 8, 50-59.	0.1	1
125	Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01. <i>Blood</i> , 2021, 138, 4464-4464.	1.4	1
126	Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. <i>Blood</i> , 2021, 138, 2313-2313.	1.4	1



#	ARTICLE	IF	CITATIONS
127	Time to tune the treatment of Ph+ ALL. <i>Blood</i> , 2015, 125, 3674-3675.	1.4	0
128	Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 232-242.	2.4	0
129	Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 3411-3419.	1.3	0
130	The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. <i>Annals of Hematology</i> , 2021, 100, 3017-3027.	1.8	0
131	High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2005, 106, 1827-1827.	1.4	0
132	Factors Associated with Relapse-Free Survival in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Imatinib-Combined Chemotherapy.. <i>Blood</i> , 2007, 110, 2813-2813.	1.4	0
133	Clinical Characteristics and Outcomes in Patients with t(8;21) Acute Myeloid Leukemia in Japan.. <i>Blood</i> , 2007, 110, 4269-4269.	1.4	0
134	Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival.. <i>Blood</i> , 2007, 110, 1852-1852.	1.4	0
135	Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study. <i>Blood</i> , 2013, 122, 2729-2729.	1.4	0
136	A Varicella Outbreak in Diffuse Large B-Cell Lymphoma Patients Receiving Rituximab-Containing Chemotherapy. <i>Blood</i> , 2014, 124, 5439-5439.	1.4	0
137	Clinical Features and Prognosis of Unselected Patients with AML and RAEB-2: Japan Adult Leukemia Study Group CS-07 Study. <i>Blood</i> , 2016, 128, 5164-5164.	1.4	0
138	Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia Improved Long Term Relapse-Free Survival: 7-Year Results from a Randomized Controlled Trial, JALSG-APL204. <i>Blood</i> , 2017, 130, 642-642.	1.4	0
139	CD56 Is an Unfavorable Prognostic Factor for Acute Promyelocytic Leukemia: Results By Multivariate Analyses in the JALSG-APL204 Study. <i>Blood</i> , 2018, 132, 2798-2798.	1.4	0
140	Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Japan. <i>Blood</i> , 2019, 134, 2045-2045.	1.4	0
141	Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1790-1790.	1.4	0
142	Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis. <i>Blood</i> , 2021, 138, 4447-4447.	1.4	0
143	Genomic Analysis of <i>NPM1</i> Mutation and <i>KMT2A</i> ( <i>MLL</i> )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01. <i>Blood</i> , 2021, 138, 4460-4460.	1.4	0
144	Significance of Marker Chromosome on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for AML. <i>Blood</i> , 2020, 136, 40-41.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01. Blood, 2020, 136, 35-36.	1.4	0
146	Genomic Analysis of <i>FLT3</i> Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. Blood, 2020, 136, 32-34.	1.4	0
147	Hematopoietic cell transplantation for mantle cell lymphoma. International Journal of Hematology, 2022, 115, 301.	1.6	0